These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30570132)

  • 1. Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.
    de Man FM; Hussaarts KGAM; de With M; Oomen-de Hoop E; de Bruijn P; van Halteren HK; van der Burg-de Graauw NCHP; Eskens FALM; van Gelder T; van Leeuwen RWF; Mathijssen RHJ
    Clin Pharmacol Ther; 2019 Jun; 105(6):1456-1461. PubMed ID: 30570132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.
    van Doorn L; Heersche N; de Man FM; de Bruijn P; Bijl I; Oomen-de Hoop E; Eskens FALM; van der Gaast A; Mathijssen RHJ; Bins S
    Clin Pharmacol Ther; 2022 Feb; 111(2):455-460. PubMed ID: 34656072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
    Veerman GDM; Hurkmans DP; Paats MS; Oomen-de Hoop E; van der Leest CH; van Thiel ERE; Aerts JGJV; van Leeuwen RW; Dingemans AC; Mathijssen RHJ
    Biomed Pharmacother; 2022 Nov; 155():113695. PubMed ID: 36126454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
    Kobayashi K; Sugiyama E; Shinozaki E; Wakatsuki T; Tajima M; Kidokoro H; Aoyama T; Nakano Y; Kawakami K; Hashimoto K; Suenaga M; Ichimura T; Ogura M; Chin K; Nakayama I; Ooki A; Takahari D; Suzuki W; Yokokawa T; Minowa Y; Hiraoka T; Suzuki K; Sato H; Hama T; Yamaguchi K
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):767-777. PubMed ID: 33635392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
    Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
    J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
    Wang-Smith L; Fort J; Zhang Y; Sostek M
    J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole.
    Pohl O; Osterloh I; Lecomte V; Gotteland JP
    Int J Clin Pharmacol Ther; 2013 Jan; 51(1):26-33. PubMed ID: 23110788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
    Veerman GDM; Hussaarts KGAM; Peric R; Oomen-de Hoop E; Landa KD; van der Leest CH; Broerse SD; Rutten HB; Belderbos HNA; Steendam CMJ; Paats MS; Koolen SLW; Dingemans AC; van Gelder T; van Leeuwen RWF; Aerts JGJV; Mathijssen RHJ
    Clin Pharmacokinet; 2021 Jan; 60(1):69-77. PubMed ID: 32557346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing.
    Sostek MB; Chen Y; Skammer W; Winter H; Zhao J; Andersson T
    Aliment Pharmacol Ther; 2003 Sep; 18(6):581-6. PubMed ID: 12969084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
    Abrahao ABK; Ko YJ; Berry S; Chan KKW
    Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
    Zhou J; Quinlan M; Glenn K; Boss H; Picard F; Castro H; Sellami D
    Br J Clin Pharmacol; 2016 Oct; 82(4):1022-9. PubMed ID: 27277189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers.
    Andersson T; Morrison D; Nagy P; Pisupati J; Schettler J; Warner TD
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):217-24. PubMed ID: 22631032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
    J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
    Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
    Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between regorafenib and atorvastatin in rats.
    Szkutnik-Fiedler D; Szałek E; Otto F; Czyrski A; Karaźniewicz-Łada M; Wolc A; Grześkowiak E; Lewandowski K; Karbownik A
    Pharmacol Rep; 2024 Oct; 76(5):1184-1195. PubMed ID: 38632186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.